ummid logo
Welcome Guest! You are here: Home » Health

First ever phase 3 clinical trial of dengue vaccine at JNMC AMU

Jawaharlal Nehru Medical College (JNMC), Aligarh Muslim University has started India's first ever phase 3 clinical trial of dengue vaccine

Friday October 11, 2024 11:30 PM, ummid.com News Network

First ever phase 3 clinical trial of dengue vaccine at JNMC AMU

Aligarh Muslim University: Jawaharlal Nehru Medical College (JNMC), Aligarh Muslim University has started India's first ever phase 3 clinical trial of dengue vaccine.

"This trial is a unique example of India’s pursuit to have an indigenous vaccine for one of the biggest public health problems and showcases our Atmanirbharta", Prof Mohammad Shameem, Chairman Department of TB and Respiratory Disease at JNMCH and Principal Investigator of the Project titled “DengiALL” said.

The study under National Health Research Priority Project has been initiated at JNMC AMU on September 17 this year.

"A two- year follow-up of the vaccinated participants has been proposed. The trial is majorly funded by ICMR and partly by Panacea Biotech, with no financial support from any external agency", Prof Shameem said.

Prof Shameem further said that there is no antiviral or licensed vaccine currently available against dengue in India.

"The complexity of developing an effective vaccine is challenged by the need to have good efficacy for all four serotypes individually. All four serotypes are found to circulate or co-circulate in many parts of India", he said.

A tetravalent dengue vaccine strain (TV003/TV005) was developed by NIH, USA and studied extensively in preclinical and clinical trials across the world. The results were promising for all four serotypes.

The strain has been transferred to three companies in India, of which Panacea Biotech is in the most advanced stage of development.

"Panacea has further worked on these strains to develop a full-fledged vaccine formulation of their own. The company possesses a process patent on this work. ", Prof Shamim said.

Phase 1 and 2 clinical trials with the Indian vaccine formulation were completed earlier in 2018-19.

"Based on the promising results of the trial, the Indian Council of Medical Research has partnered with Panacea Biotech to undertake a full-fledged phase 3 clinical trial in more than 10,335 healthy adults at 19 sites spread across 18 States/UTs of India", Prof Shamim said.

Follow ummid.com WhatsApp Channel for all the latest updates.

Select Language To Read in Urdu, Hindi, Marathi or Arabic.

 

Top Stories

For all the latest News, Opinions and Views, download ummid.com App.

Google News

 Post Comments
Note: By posting your comments here you agree to the terms and conditions of www.ummid.com

....
..